Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute … – Sacramento Bee

Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute
Sacramento Bee
One of these agents, R343, an inhaled SYK inhibitor, will be entering a Phase 2 clinical study later this summer in mild to moderate asthmatic patients. The other, R256, an inhaled IL13 signaling/JAK inhibitor, is potentially useful in controlling
Rigel moving asthma drug into mid-stage trialBizjournals.com (blog)

all 11 news articles »

View full post on asthma – Google News

Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute … – MarketWatch (press release)

Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute
MarketWatch (press release)
SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire via COMTEX/ — Rigel Pharmaceuticals, Inc., (NASDAQ:RIGL) is expanding its respiratory franchise by focusing on two innovative, comprehensive treatment alternatives for patients with asthma.

and more »

View full post on asthma – Google News

Pfizer returns asthma drug development to Rigel – Ventura County Star

Pfizer returns asthma drug development to Rigel
Ventura County Star
(AP) – Rigel Pharmaceuticals Inc. said Friday it will take over development from Pfizer Inc. of a potential allergic asthma treatment that recently completed several early-stage clinical trials. The South San Francisco, Calif., development-stage
Rigel Assumes Development Responsibility For Inhaled AsthmaBioResearch Online (press release)
Losing Biobucks as Pharma Reshuffles Its DeckSeeking Alpha
Pfizer returns asthma drug candidate rights to Rigel Pharma; latter narrows lossesThe Pharma Letter
Pharma Times
all 6 news articles »

View full post on asthma – Google News

Rigel Assumes Development Responsibility For Inhaled Asthma – BioResearch Online (press release)

Rigel Assumes Development Responsibility For Inhaled Asthma
BioResearch Online (press release)
South San Francisco, CA /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials.

View full post on asthma – Google News

Rigel Assumes Development Responsibility For Inhaled Asthma Therapy – Medical News Today (press release)

Rigel Assumes Development Responsibility For Inhaled Asthma Therapy
Medical News Today (press release)
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer Inc. is returning full rights to the

and more »

View full post on asthma – Google News

Pfizer returns asthma drug development to Rigel – Forbes

Pfizer returns asthma drug development to Rigel
Forbes
Rigel Pharmaceuticals Inc. said Friday it will take over development from Pfizer Inc. of a potential allergic asthma treatment that recently completed several early-stage clinical trials. The South San Francisco, Calif., development-stage company said
Rigel says Pfizer returns asthma therapy rightsReuters
Rigel Assumes Development Responsibility for Inhaled Asthma TherapyPR Newswire (press release)
Pfizer returns allergic asthma drug to RigelFierceBiotech
Xconomy
all 27 news articles »

View full post on asthma – Google News

Pfizer returns allergic asthma drug to Rigel – FierceBiotech

Pfizer returns allergic asthma drug to Rigel
FierceBiotech
Pfizer's decision to ends its allergy and respiratory R&D work has prompted the company return rights to the R343 program for allergic asthma to Rigel Pharmaceuticals. The drug has shown promise in Phase I trials and Rigel plans to begin designing a
Rigel says Pfizer returns asthma therapy rightsReuters
Rigel Assumes Development Responsibility for Inhaled Asthma TherapyPR Newswire (press release)
Pfizer Hands Back Rigel DrugXconomy

all 16 news articles »

View full post on asthma – Google News